Pere Santamaria

List of Publications by Year
in descending order

128 papers	9,482 citations	41344 49 h-index	38395 95 g-index
135 all docs	135 docs citations	135 times ranked	9690 citing authors

#	Article	IF	Citations
1	Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nature Immunology, 2006, 7, 83-92.	14.5	718
2	Expanding antigen-specific regulatory networks to treat autoimmunity. Nature, 2016, 530, 434-440.	27.8	409
3	Nanoparticle-Based Immunotherapy for Cancer. ACS Nano, 2015, 9, 16-30.	14.6	391
4	Identification of the Î² cell antigen targeted by a prevalent population of pathogenic CD8+T cells in autoimmune diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8384-8388.	7.1	353
5	Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nature Genetics, 2007, 39, 329-337.	21.4	333
6	Spontaneous Autoimmune Diabetes in Monoclonal T Cell Nonobese Diabetic Mice. Journal of Experimental Medicine, 1997, 186, 1663-1676.	8.5	319
7	Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature, 2000, 406, 739-742.	27.8	318
8	TRPV1+ Sensory Neurons Control Î² Cell Stress and Islet Inflammation in Autoimmune Diabetes. Cell, 2006, 127, 1123-1135.	28.9	308
9	Reversal of Autoimmunity by Boosting Memory-like Autoregulatory T Cells. Immunity, 2010, 32, 568-580.	14.3	284
10	NKG2D Blockade Prevents Autoimmune Diabetes in NOD Mice. Immunity, 2004, 20, 757-767.	14.3	272
11	CD40 Ligation Releases Immature Dendritic Cells from the Control of Regulatory CD4+CD25+ T Cells. Immunity, 2003, 19, 877-889.	14.3	259
12	Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. Journal of Clinical Investigation, 2003, 111, 217-223.	8.2	201
13	IL-1 Receptor Deficiency Slows Progression to Diabetes in the NOD Mouse. Diabetes, 2004, 53, 113-121.	0.6	192
14	A Mechanism for the Major Histocompatibility Complexâ€“linked Resistance to Autoimmunity. Journal of Experimental Medicine, 1997, 186, 1059-1075.	8.5	188
15	Autoreactive CD8 T Cells in Organ-Specific Autoimmunity. Immunity, 2002, 17, 1-6.	14.3	178
16	Exendin-4 Improves Reversal of Diabetes in NOD Mice Treated with Anti-CD3 Monoclonal Antibody by Enhancing Recovery of Î²-Cells. Endocrinology, 2007, 148, 5136-5144.	2.8	161
17	Antigen-specific therapeutic approaches for autoimmunity. Nature Biotechnology, 2019, 37, 238-251.	17.5	154
18	T Cell Islet Accumulation in Type 1 Diabetes Is a Tightly Regulated, Cell-Autonomous Event. Immunity, 2009, 31, 643-653.	14.3	142

#	Article	IF	Citations
19	Cellular and Molecular Mechanisms for the Initiation and Progression of Î² Cell Destruction Resulting from the Collaboration Between Macrophages and T Cells. Autoimmunity, 1998, 27, 109-122.	2.6	140
20	Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide. Nature Medicine, 2005, 11, 645-652.	30.7	132
21	MHC Class II Polymorphisms, Autoreactiveâ€‰T-Cells, and Autoimmunity. Frontiers in Immunology, 2013, 4, 321.	4.8	123
22	CD8+ T cells in autoimmunity. Current Opinion in Immunology, 2005, 17, 624-631.	5.5	121
23	Adenosine Deamination Sustains Dendritic Cell Activation in Inflammation. Journal of Immunology, 2007, 179, 1884-1892.	0.8	121
24	IL-1Î±, IL-1Î², and IFN-Î³ mark Î² cells for Fas-dependent destruction by diabetogenic CD4+ T lymphocytes. Journal of Clinical Investigation, 2000, 105, 459-468.	8.2	115
25	Peptideâ€"MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices. Nature Nanotechnology, 2017, 12, 701-710.	31.5	114
26	Individual Nonobese Diabetic Mice Exhibit Unique Patterns of CD8+ T Cell Reactivity to Three Islet Antigens, Including the Newly Identified Widely Expressed Dystrophia Myotonica Kinase. Journal of Immunology, 2004, 173, 6727-6734.	0.8	109
27	Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. Journal of Clinical Investigation, 2003, 111, 217-223.	8.2	108
28	Tracking the Recruitment of Diabetogenic CD8+ T-Cells to the Pancreas in Real Time. Diabetes, 2004, 53, 1459-1466.	0.6	107
29	Perforin-independent Î²-cell destruction by diabetogenic CD8+ T lymphocytes in transgenic nonobese diabetic mice. Journal of Clinical Investigation, 1999, 103, 1201-1209.	8.2	107
30	A Gut Microbial Mimic that Hijacks Diabetogenic Autoreactivity to Suppress Colitis. Cell, 2017, 171, 655-667.e17.	28.9	106
31	Chapter 4 CD8+ T Cells in Type 1 Diabetes. Advances in Immunology, 2008, 100, 79-124.	2.2	105
32	Synergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleukin-1 Blockade. Diabetes, 2012, 61, 145-154.	0.6	98
33	In Situ Î² Cell Death Promotes Priming of Diabetogenic CD8 T Lymphocytes. Journal of Immunology, 2002, 168, 1466-1472.	0.8	96
34	Suppressor of Cytokine Signaling-1 Overexpression Protects Pancreatic Î² Cells from CD8+ T Cell-Mediated Autoimmune Destruction. Journal of Immunology, 2004, 172, 5714-5721.	0.8	96
35	Developmental control of CD8+ T cellâ€"avidity maturation in autoimmune diabetes. Journal of Clinical Investigation, 2005, 115, 1879-1887.	8.2	96
36	On the Pathogenicity of Autoantigen-Specific T-Cell Receptors. Diabetes, 2008, 57, 1321-1330.	0.6	89

#	Article	IF	Citations
37	Nanoparticle-based autoimmune disease therapy. Clinical Immunology, 2015, 160, 3-13.	3.2	84
38	Nanoparticles for Immune Stimulation Against Infection, Cancer, and Autoimmunity. ACS Nano, 2018, 12, 10621-10635.	14.6	79
39	Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines. Nature Communications, 2019, 10, 2150.	12.8	73
40	TLR9 Blockade Inhibits Activation of Diabetogenic CD8+ T Cells and Delays Autoimmune Diabetes. Journal of Immunology, 2010, 184, 5645-5653.	0.8	70
41	Identification of novel IGRP epitopes targeted in type 1 diabetes patients. Clinical Immunology, 2008, 127, 359-365.	3.2	69
42	Effector lymphocytes in autoimmunity. Current Opinion in Immunology, 2001, 13, 663-669.	5.5	67
43	Transient Upregulation of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Human Chorionic Gonadotropin Downregulates Autoimmune Diabetes. Diabetes, 2007, 56, 1686-1693.	0.6	67
44	The Long and Winding Road to Understanding and Conquering Type 1 Diabetes. Immunity, 2010, 32, 437-445.	14.3	67
45	Expansion of the Antigenic Repertoire of a Single T Cell Receptor upon T Cell Activation. Journal of Immunology, 2001, 167, 655-666.	0.8	65
46	Highly Sensitive and Specific Multiplex Antibody Assays To Quantify Immunoglobulins M, A, and G against SARS-CoV-2 Antigens. Journal of Clinical Microbiology, 2021, 59, .	3.9	64
47	B-Cells Promote Intra-Islet CD8+ Cytotoxic T-Cell Survival to Enhance Type 1 Diabetes. Diabetes, 2008, 57, 909-917.	0.6	56
48	Cross-Priming of Diabetogenic T Cells Dissociated from CTL-Induced Shedding of Î² Cell Autoantigens. Journal of Immunology, 2003, 171, 6900-6909.	0.8	53
49	IL-2 and its high-affinity receptor: Genetic control of immunoregulation and autoimmunity. Seminars in Immunology, 2009, 21, 363-371.	5.6	52
50	In situ recognition of autoantigen as an essential gatekeeper in autoimmune CD8⁺T cell inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9317-9322.	7.1	52
51	Autoimmunity to Both Proinsulin and IGRP Is Required for Diabetes in Nonobese Diabetic 8.3 TCR Transgenic Mice. Journal of Immunology, 2008, 180, 4458-4464.	0.8	51
52	Nanoparticleâ€based approaches to immune tolerance for the treatment of autoimmune diseases. European Journal of Immunology, 2018, 48, 751-756.	2.9	51
53	Nanomedicine in autoimmunity. Immunology Letters, 2014, 158, 167-174.	2.5	47
54	The Proline-Rich Sequence of CD3Îµ as an Amplifier of Low-Avidity TCR Signaling. Journal of Immunology, 2008, 181, 243-255.	0.8	46

#	Article	IF	Citations
55	Mast Cells Regulate the Magnitude and the Cytokine Microenvironment of the Contact Hypersensitivity Response. American Journal of Pathology, 2008, 172, 1638-1649.	3.8	45
56	Islet-infiltrating B-Cells in Nonobese Diabetic Mice Predominantly Target Nervous System Elements. Diabetes, 2005, 54, 69-77.	0.6	42
57	CD154-Dependent Priming of Diabetogenic CD4+ T Cells Dissociated from Activation of Antigen-Presenting Cells. Immunity, 2002, 16, 719-732.	14.3	40
58	Autoreactive Cytotoxic T Lymphocytes Acquire Higher Expression of Cytotoxic Effector Markers in the Islets of NOD Mice after Priming in Pancreatic Lymph Nodes. American Journal of Pathology, 2011, 178, 2716-2725.	3.8	40
59	Antigen-Specific Therapeutic Approaches in Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007773-a007773.	6.2	40
60	TNF Receptor 1 Deficiency Increases Regulatory T Cell Function in Nonobese Diabetic Mice. Journal of Immunology, 2011, 187, 1702-1712.	0.8	39
61	CCL4 Protects From Type 1 Diabetes by Altering Islet Â-Cell-Targeted Inflammatory Responses. Diabetes, 2007, 56, 809-817.	0.6	34
62	Intraâ€islet proliferation of cytotoxic <scp>T</scp> lymphocytes contributes to insulitis progression. European Journal of Immunology, 2012, 42, 1717-1722.	2.9	34
63	Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19. BMC Medicine, 2021, 19, 155.	5.5	34
64	Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a â€œone size fits allâ€• approach?. Journal of Molecular Medicine, 2011, 89, 733-742.	3.9	33
65	Cytokines and Chemokines in Autoimmune Disease: An Overview. Advances in Experimental Medicine and Biology, 2003, 520, 1-7.	1.6	32
66	In vivo imaging of a diabetogenic CD8+ T cell response during type 1 diabetes progression. Magnetic Resonance in Medicine, 2008, 59, 712-720.	3.0	31
67	Cutting Edge: CD28 Engagement Releases Antigen-Activated Invariant NKT Cells from the Inhibitory Effects of PD-1. Journal of Immunology, 2009, 182, 6644-6647.	0.8	31
68	<i>Idd9.1</i>Locus Controls the Suppressive Activity of FoxP3+CD4+CD25+ Regulatory T-Cells. Diabetes, 2010, 59, 272-281.	0.6	31
69	Ubiquitous antigen-specific T regulatory type 1 cells variably suppress hepatic and extrahepatic autoimmunity. Journal of Clinical Investigation, 2020, 130, 1823-1829.	8.2	31
70	Loss of immune tolerance to IL-2 in type 1 diabetes. Nature Communications, 2016, 7, 13027.	12.8	28
71	Gut Microbial Antigenic Mimicry in Autoimmunity. Frontiers in Immunology, 2022, 13, 873607.	4.8	28
72	The role of low avidity T cells in the protection against type 1 diabetes: A modeling investigation. Journal of Theoretical Biology, 2009, 256, 126-141.	1.7	27

#	Article	IF	Citations
73	CD8+ Tregs in autoimmunity: learning â€œselfâ€•control from experience. Cellular and Molecular Life Sciences, 2011, 68, 3781-3795.	5.4	27
74	<scp>IL</scp>â€2 promotes the function of memoryâ€like autoregulatory <scp>CD</scp>8⁺<scp>T</scp> cells but suppresses their development via <scp>F</scp>ox<scp>P</scp>3⁺<scp>T</scp>reg cells. European Journal of Immunology, 2013, 43, 394-403.	2.9	26
75	T-Cell Tolerance by Dendritic Cells and Macrophages as a Mechanism for the Major Histocompatibility Complex-Linked Resistance to Autoimmune Diabetes. Diabetes, 2002, 51, 325-338.	0.6	23
76	High Levels of Adenosine Deaminase on Dendritic Cells Promote Autoreactive T Cell Activation and Diabetes in Nonobese Diabetic Mice. Journal of Immunology, 2011, 186, 6798-6806.	0.8	23
77	In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells. PLoS ONE, 2019, 14, e0223339.	2.5	23
78	Contribution of a Non-Î²-Cell Source to Î²-Cell Mass during Pregnancy. PLoS ONE, 2014, 9, e100398.	2.5	23
79	In vivo effects of cytokines on pancreatic Î²â€cells in models of type I diabetes dependent on CD4 + T lymphocytes. Immunology and Cell Biology, 2009, 87, 178-185.	2.3	21
80	DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8+ T cells independently of PD-1 and PD-L1. International Immunology, 2013, 25, 651-660.	4.0	21
81	Prolactin as an Adjunct for Type 1 Diabetes Immunotherapy. Endocrinology, 2016, 157, 150-165.	2.8	19
82	Taming autoimmunity: Translating antigen-specific approaches to induce immune tolerance. Journal of Experimental Medicine, 2019, 216, 247-250.	8.5	19
83	Progression of spontaneous autoimmune diabetes is associated with a switch in the killing mechanism used by autoreactive CTL. International Immunology, 2004, 16, 1657-1662.	4.0	17
84	Local Autoantigen Expression as Essential Gatekeeper of Memory T-Cell Recruitment to Islet Grafts in Diabetic Hosts. Diabetes, 2013, 62, 905-911.	0.6	16
85	On How Monospecific Memory-Like Autoregulatory CD8+ T Cells Can Blunt Diabetogenic Autoimmunity: A Computational Approach. Journal of Immunology, 2010, 185, 5962-5972.	0.8	15
86	Antidiabetogenic MHC class II promotes the differentiation of MHC-promiscuous autoreactive T cells into FOXP3⁺regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3471-3476.	7.1	15
87	Dendritic Cellâ€"Dependent In Vivo Generation of Autoregulatory T Cells by Antidiabetogenic MHC Class II. Journal of Immunology, 2013, 191, 70-82.	0.8	14
88	Development of Memory-Like Autoregulatory CD8+ T Cells Is CD4+ T Cell Dependent. Journal of Immunology, 2011, 187, 2859-2866.	0.8	13
89	Complete Diabetes Protection Despite Delayed Thymic Tolerance in NOD8.3 TCR Transgenic Mice Due to Antigen-Induced Extrathymic Deletion of T Cells. Diabetes, 2012, 61, 425-435.	0.6	13
90	Quantifying the importance of pMHC valency, total pMHC dose and frequency on nanoparticle therapeutic efficacy. Immunology and Cell Biology, 2013, 91, 350-359.	2.3	13

#	Article	IF	Citations
91	E2-2 Dependent Plasmacytoid Dendritic Cells Control Autoimmune Diabetes. PLoS ONE, 2015, 10, e0144090.	2.5	13
92	Increased yields and biological potency of knob-into-hole-based soluble MHC class II molecules. Nature Communications, 2019, 10, 4917.	12.8	13
93	Turning Human Epidermis Into Pancreatic Endoderm. Review of Diabetic Studies, 2010, 7, 158-167.	1.3	13
94	Effector lymphocytes in islet cell autoimmunity. Reviews in Endocrine and Metabolic Disorders, 2003, 4, 271-280.	5.7	12
95	Kinetic Evolution of a Diabetogenic CD8+ T Cell Response. Annals of the New York Academy of Sciences, 2003, 1005, 88-97.	3.8	12
96	Liver-specific T regulatory type-1 cells program local neutrophils to suppress hepatic autoimmunity via CRAMP. Cell Reports, 2021, 34, 108919.	6.4	12
97	Evolution of nanomedicines for the treatment of autoimmune disease: From vehicles for drug delivery to inducers of bystander immunoregulation. Advanced Drug Delivery Reviews, 2021, 176, 113898.	13.7	12
98	Reversal of autoimmunity by mixed chimerism enables reactivation of Î² cells and transdifferentiation of Î± cells in diabetic NOD mice. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31219-31230.	7.1	11
99	The pathogenicity of self-antigen decreases at high levels of autoantigenicity: a computational approach. International Immunology, 2010, 22, 571-582.	4.0	10
100	An indirect role for NK cells in a CD4 + Tâ€cellâ€dependent mouse model of type I diabetes. Immunology and Cell Biology, 2012, 90, 243-247.	2.3	10
101	Beyond HLA-A*0201: New HLA-Transgenic Nonobese Diabetic Mouse Models of Type 1 Diabetes Identify the Insulin C-Peptide as a Rich Source of CD8+ T Cell Epitopes. Journal of Immunology, 2012, 188, 5766-5775.	0.8	9
102	Peptide-MHC-Based Nanomedicines for the Treatment of Autoimmunity: Engineering, Mechanisms, and Diseases. Frontiers in Immunology, 2020, 11, 621774.	4.8	9
103	Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of Autoimmunity. Frontiers in Immunology, 2021, 12, 684240.	4.8	9
104	Quantifying immunoregulation by autoantigenâ€specific Tâ€regulatory type 1 cells in mice with simultaneous hepatic and extraâ€hepatic autoimmune disorders. Immunology, 2020, 161, 209-229.	4.4	8
105	Recognition of Multiple Hybrid Insulin Peptides by a Single Highly Diabetogenic T-Cell Receptor. Frontiers in Immunology, 2021, 12, 737428.	4.8	8
106	The pro-apoptotic BH3-only protein Bid is dispensable for development of insulitis and diabetes in the non-obese diabetic mouse. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 822-830.	4.9	7
107	Autoantigen Recognition Is Required for Recruitment of IGRP206â€"214-Autoreactive CD8+ T Cells but Is Dispensable for Tolerance. Journal of Immunology, 2012, 189, 2975-2984.	0.8	7
108	The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development. Diabetologia, 2013, 56, 2659-2668.	6.3	7

#	Article	IF	Citations
109	Extremely short bioavailability and fast pharmacodynamic effects of pMHC-based nanomedicines. Journal of Controlled Release, 2021, 338, 557-570.	9.9	7
110	Re-programming mouse liver-resident invariant natural killer T cells for suppressing hepatic and diabetogenic autoimmunity. Nature Communications, 2022, 13, .	12.8	7
111	Spontaneous Autoimmunity Sufficiently Potent to Induce Diabetes Mellitus Is Insufficient to Protect against Insulinoma. Journal of Immunology, 2009, 183, 1705-1714.	0.8	6
112	Immunomodulatory and immunoregulatory nanomedicines for autoimmunity. Seminars in Immunology, 2021, 56, 101535.	5.6	6
113	A Monoclonal Antibody Against the Extracellular Domain of Mouse and Human Epithelial V-like Antigen 1 Reveals a Restricted Expression Pattern Among CD4- CD8- Thymocytes. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2014, 33, 305-311.	1.6	4
114	The Cross-Priming Capacity and Direct Presentation Potential of an Autoantigen Are Separable and Inversely Related Properties. Journal of Immunology, 2014, 193, 3296-3307.	0.8	3
115	De novo germline mutation in the dual specificity phosphatase 10 gene accelerates autoimmune diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	3
116	Genetic and Therapeutic Control of Diabetogenic CD8+ T Cells. Novartis Foundation Symposium, 2008, 292, 130-140.	1.1	2
117	Antigen-specific nanomedicines for the treatment of autoimmune disease: target cell types, mechanisms and outcomes. Current Opinion in Biotechnology, 2022, 74, 285-292.	6.6	2
118	Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. Canadian Liver Journal, 2021, 4, 401-425.	0.9	1
119	Cytotoxic lymphocytes, apoptosis, and autoimmunity. , 2005, , 188-218.		0
120	T Cells and Autoimmunity. , 2006, , 59-82.		0
121	Correction: Levels of Adenosine Deaminase on Dendritic Cells Promote Autoreactive T Cell Activation and Diabetes in Nonobese Diabetic Mice. Journal of Immunology, 2011, 187, 2031-2031.	0.8	0
122	Interview: Disease-specific therapeutic interventions in Type 1 diabetes. Diabetes Management, 2013, 3, 363-365.	0.5	0
123	Prolactin Improved Anti-CD3-Mediated Diabetes Cure in NOD Mice. Canadian Journal of Diabetes, 2014, 38, S65.	0.8	0
124	260-OR: Transdifferentiation of a-Cells and Redifferentiation of InsulinLo ÃŸ-Cells Dominate ÃŸ-Cell Regeneration in Late-Stage Diabetic NOD Mice Cured with Induction of Mixed Chimerism and Administration of Gastrin and Epidermal Growth Factor. Diabetes, 2020, 69, 260-OR.	0.6	0
125	In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells. , 2019, 14, e0223339.		0
126	In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells. , 2019, 14, e0223339.		0

#	Article	IF	Citations
127	In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells. , 2019, 14, e0223339.		0
128	In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells. , 2019, 14, e0223339.		0